Biotinylated Human CLEC9A Protein (Primary Amine Labeling)
Catalog No: CLEC9A-HF002
- Species
- Human
- Expression System
- HEK293
- Tag
- an hFc (IgG1)
- Activity
- Activity verified
Product overview
Recombinant Biotinylated Human CLEC9A Protein (Primary Amine Labeling) is expressed in HEK293 cells with an hFc (IgG1) tag at the N-terminus. It contains amino acid residues Lys57-Val241 (UniProt accession: Q6UXN8).
Product Details
- Molecular Aliases
- CD370; CLEC9A; 9830005G06Rik; DNGR-1; HEEE9341; UNQ9341;DNGR1
- Protein Length
- Lys57-Val241
- Expression System
- HEK293
- Theoretical Molecular Weight
- The protein has a predicted MW of 48.5 kDa. Due to glycosylation, the protein migrates to 55-70 kDa based on Bis-Tris PAGE result.
- Purity
- > 95% as determined by Bis-Tris PAGE > 90% as determined by HPLC
- Endotoxin
- Less than 1 EU per μg by the LAL method.
- Buffer / Formulation
- Lyophilized from 0.22 μm filtered solution in PBS, 100mM L-arginine (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
- State
- Lyophilized
- Storage Conditions
- -20 to -80°C for 12 months as supplied from date of receipt. -80°C for 3 months after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
- Reconstitution Advice
- Dissolve the lyophilized protein in distilled water. Please refer to the Certificate of Analysis for detailed instructions.
Data Display
Biotinylated Human CLEC9A on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.
The purity of Biotinylated Human CLEC9A is greater than 90% as determined by SEC-HPLC.
Immobilized Anti-CLEC9A Antibody, hFc Tag at 0.5μg/ml (100μl/well) on the plate. Dose response curve for Biotinylated Human CLEC9A, hFc Tag with the EC50 of 30.9ng/ml determined by ELISA (QC Test).
Background
CLEC9A is a recently discovered C-type lectin receptor involved in sensing necrotic cells. In humans, this receptor is selectively expressed by BDCA3(+) myeloid dendritic cells (mDCs), which have been proposed to be the main human cross-presenting mDCs and may represent the human homologue of murine CD8(+) DCs. In mice, it was demonstrated that antigens delivered with antibodies to CLEC9A are presented by CD8(+) DCs to both CD4(+) and CD8(+) T cells and induce antitumor immunity in a melanoma model.
References
- Schreibelt G, Klinkenberg LJ, Cruz LJ, Tacken PJ, Tel J, Kreutz M, Adema GJ, Brown GD, Figdor CG, de Vries IJ. The C-type lectin receptor CLEC9A mediates antigen uptake and (cross-)presentation by human blood BDCA3+ myeloid dendritic cells. Blood. 2012 Mar 8;119(10):2284-92. doi: 10.1182/blood-2011-08-373944. Epub 2012 Jan
- PMID:
- Note: HPLC results always come from liquid protein, due to absorption peak interference of trehalose in lyophilized powder.
Have questions about this product?
Our technical team can help with product selection, application questions and order support.